Cognitive impairments in some cardiovascular and somatic diseases
https://doi.org/10.14412/2074-2711-2015-2-93-100
Abstract
The paper gives an update on the pathogenesis, clinical presentation, and pathomorphology of cognitive impairments (CIs) in different autoimmune, endocrine, and infectious diseases: systemic lupus erythematosus, Sjögren’s syndrome, Behchet’s disease, primary angiitis of the central nervous system, polyarteritis nodosa, cryoglobulinemic vasculitis, hypothyroidism, herpetic lesion, and neurosyphilis. It is noted that treatment for CIs should be individual in terms of virulence factors. In vascular CIs, therapy should be aimed primarily at modifying risk factors and eliminating or reducing chronic brain ischemia. The prevention of progressive CI encompasses antihypertensive and antithrombotic therapies and surgical correction of atherosclerotic great artery stenosis. Control of hyperlipidemia, hyperglycemia and treatment of other somatic diseases are also of great importance. Such patients are usually given cetylcholinesterase inhibitors, acetylcholine precursors, antiglutamatergic agents, and metabolic and vascular drugs. By taking into account brain ischemia/ hypoxia in the above diseases, it is shown to be advisable to use antioxidants, cerebral active agents in particular, which have a complex neurometabolic effect.
About the Author
N. V. Pizova
Department of Neurology and Medical Genetics with Course of Neurosurgery, Yaroslavl State Medical University, Ministry of Health of Russia, Yaroslavl, Russia 5, Revolutsionnaya St., Yaroslavl 150000
Russian Federation
Russian Federation
References
1. Cуслина ЗА, Фонякин АВ, Гераскина ЛА и др. Практическая кардионеврология. Москва: ИМА-ПРЕСС; 2010. С. 205–7. [Suslina ZA, Fonyakin AV, Geraskina LA, et al. Prakticheskaya kardionevrologiya [Practical cardioneurology]. Moscow: IMA-PRESS; 2010. P. 205–7.]
2. Киландер Л, Ниман Н, Боберг М и др. Взаимосвязь артериальной гипертензии с когнитивными нарушениями: Результаты 20-летнего наблюдения 999 пациентов. Обзоры клинической кардиологии. 2005;(2):37–49. [Kilander L, Niman N, Boberg M i dr. The relationship of hypertension with cognitive impairment: results of a 20-year observational study of 999 patients. Obzory klinicheskoi kardiologii. 2005;(2):37–49. (In Russ.)].
3. Сервилла ДА, Принс М, Лавстоун С и др. Долгосрочные предикторы результатов оценки когнитивных функций в когорте пожилых лиц, страдающих артериальной гипертензией. Обзоры клинической кардиологии. 2005;(2):2–12. [Servilla DA, Prins M, Lavstoun S i dr. Long-term predictors of outcome of assessment of cognitive function in a cohort of elderly suffering from hypertension. Obzory klinicheskoi kardiologii. 2005;(2):2– 2. (In Russ.)].
4. Шевченко ОП, Праскурничий ЕА, Яхно НН, Парфенов ВА. Артериальная гипертония и церебральный инсульт. Москва: Реафарм; 2001. 192 с. [Shevchenko OP, Praskurnichii EA, Yakhno NN, Parfenov VA. Arterial'naya gipertoniya i tserebral'nyi insul't [Arterial hypertension and cerebral stroke]. Moscow: Reafarm; 2001. 192 p.]
5. Elias PK, DХAgostino RB, Elias MF, Wolf PA. Blood pressure, hypertension, and age as risk factors for poor cognitive performance. Exp Aging Res. 1995 Oct-Dec;21(4):393–417.
6. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised oubleblind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998 Oct 24;352(9137):1347–51.
7. Singh-Manoux A, Marmot M. High blood pressure was associated with cognitive function in middle-age in the Whitehall II study. J Clin Epidemiol. 2005 Dec;58(12):1308–15.
8. Starr JM, Whalley LJ, Inch S, Shering PA. Blood pressure and cognitive functions in healthy old people. J Am Geriatr Soc. 1993;41:153–6.
9. Tzourio C, Dufouil C, Ducimetiere P, Alperovitch A. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Group. Neurology. 1999 Dec 10;53(9):1948–52.
10. Launer LJ, Masaki K, Petrovitch H, et al. The association between midlife blood pressure level and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995 Dec 20;274(23):1846–51.
11. Левин ОС. Диагностика и лечение деменции в клинической практике. Москва: МЕД пресс-информ; 2010. 256 с. [Levin OS. Diagnostika i lechenie dementsii v klinicheskoi praktike [Diagnosis and treatment of dementia in clinical practice]. Moscow: MED pressinform; 2010. 256 p.]
12. Ruitenberg A, Skoog I, Ott A, et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord. 2001 Jan- Feb;12(1):33–9.
13. Kivipelto M, Ngandu T, Laatikainen T, et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006 Sep;5(9):735–41.
14. Elkins JS, Yaffe K, Cauley JA, et al. Preexisting hypertension and the impact of stroke on ognitive function. Ann Neurol. 2005 Jul;58(1):68–74.
15. Еремина ОВ. Когнитивные нарушения у больных артериальной гипертонией (частота, диагностика, лечение): Дис. ... канд. мед. наук. Иркутск; 2007. [Eremina OV. Kognitivnye narusheniya u bol'nykh arterial'noi gipertoniei (chastota, diagnostika, echenie): is. ... kand. med. nauk [Cognitive impairment in patients with arterial hypertension (frequency, iagnosis, treatment). Diss. ... cand. mrd. sci]. Irkutsk; 2007. (In Russ.)].
16. Левин ОС, Дамулин ИВ. Диффузные изменения белого вещества (лейкоареоз) и проблема сосудистой деменции. В кн. Достижения в нейрогериатрии. Яхно НН, Дамулин ИВ, редакторы. Москва: ММА; 1995. С. 189–231. [Levin OS, Damulin IV. Diffuse changes in white matter (lykouras) and the problem of vascular dementia. In: Dostizheniya v eirogeriatrii [Advances in neurogeriatrics]. Yakhno NN, Damulin IV, editors. Moscow: MMA; 1995. P. 189–231.]
17. Мартынов АИ, Шмырев ВИ, Остроумова ОИ и др. Особенности поражения белого вещества головного мозга у пожилых больных с артериальной гипертензией. Клиническая медицина. 2000;(6):11–5. [Martynov AI, Shmyrev VI, Ostroumova OI, et al. Characteristics of lesions in the white matter of the brain in elderly patients with arterial hypertension. Klinicheskaya meditsina. 2000;(6):11–5. (In Russ.)].
18. Яхно НН, Левин ОС, Дамулин ИВ. Сопоставление клинических и МРТ-данных при дисциркуляторной энцефалопатии. Сообщение 2: когнитивные нарушения. Неврологический журнал. 2001;6(3):10–9. [Yakhno NN, Levin OS, Damulin IV. Correlation of clinical and MRI data with discirculatory encephalopathy. Message 2: cognitive impairments. Nevrologicheskii zhurnal. 2001;6(3):10–9. (In Russ.)].
19. Алехин АН, Трифонова ЕА, Лебедев ДС, Михайлов ЕН. Психологические проблемы в аритмологии (на модели фибрилляции предсердий). Вестник аритмологии. 2011;63(63):45–54. [Alekhin AN, Trifonova EA, Lebedev DS, Mikhailov EN. Psychological problems in Arrhythmology (on the model of atrial fibrillation). Vestnik aritmologii. 2011;63(63):45–54. (In Russ.)].
20. Puccio D, Novo G, Baiamonte V, et al. Atrial fibrillation and mild cognitive impairment: what correlation? Minerva Cardioangiol. 2009 Apr;57(2):143–50.
21. Skoog I, Gustafson D. Clinical trials for primary prevention in dementia. In: Dementia therapeutic research. Rockwood K, Gauthier S, editors. London and New York: Taylor a Francis; 2006. P. 189–212.
22. Левин ОС. Когнитивные нарушения в практике терапевта: заболевания сердечно- сосудистой системы. Consilium Medicum. 009;11(2): 55–61. [Levin OS. Cognitive impairment in the practice of the therapist: diseases of the cardiovascular system. Consilium Medicum. 2009;11(2): 55–61.]
23. Lane DA, Langman СМ, Lip GY. Illness perceptions, affective response, and ealthrelated quality of life in patients with atrial fibrillation. J Psychosom Res. 2009 Mar;66(3):203–10. doi: 10.1016/j.jpsychores.2008.10.007.
24. Shi J, Yang SH, Stubley L, et al. Hypoperfusion induces overexpression of betaamyloid precursor protein mRNA in a focal ischemic rodent model. Brain Res. 2000 Jan 17;853(1):1–4.
25. Sparks DL, Scheff SW, Liu H, et al. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci. 1995 Aug;131(2):162–9.
26. Bennett SJ, Sauve MJ. Cognitive deficits in patients with heart failure: a review of the iterature. J Cardiovasc Nurs. 2003 Jul-Aug; 18(3):219–42.
27. Vogels RL, Scheltens P, Schroeder-Tanka JM, Weinstein HC. Cognitive impairment in heart failure: a systematic review of the literature. Eur J Heart Fail. 2007 May;9(5):440–9. Epub 2006 Dec 14.
28. Vogels RL, Oosterman JM, van Harten B, et al. Profile of cognitive impairment in chronic heart failure. J Am Geriatr Soc. 2007 Nov;55(11):1764–70. Epub 2007 Aug 28.
29. Bauer LC, Johnson JK, Pozehl BJ. Cognition in heart failure: an overview of the concepts and their measures. J Am Acad Nurse Pract. 2011 Nov;23(11):577–85. doi: 10.1111/j.1745-7599.2011.00668.x.
30. Trojano L, Antonelli Incalzi R, Acanfora D, et al; Congestive Heart Failure Italian Study Investigators. Cognitive impairment: a key feature of congestive heart failure in the elderly. J Neurol. 2003 Dec;250(12):1456–63.
31. Zuccala G, Onder G, Marzetti E, et al; GIFA Study Group. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J. 2005 Feb;26(3):226–33. Epub 2004 Dec 6.
32. Jefferson A, Benjamin E. Cardiovascular disease, cognitive decline and dementia. In: Vascular cognitive impairment in clinical practice. L.Wahlung, Erkinjuntti T, Gauthier S, ditors. Cambridge; 2009. P. 166–77.
33. Cacciatore F, Abete P, Ferrara N, et al. Congestive heart failure and cognitive mpairment in an older population. J Am Geriatr Soc. 1998 Nov;46(11):1343–8.
34. Pullicino PM, Hart J. Cognitive Impairment in congestive heart failure. Neurology. 2001 Dec 11;57(11):1945–6.
35. Gruhn N, Larsen FS, Boesgaard S, et al. Cerebral blood flow in patients with chronic heart failure before and after heart transplantation.Stroke. 2001 Nov;32(11):2530–3.
36. Alves TC, Rays J, Fraguas R Jr, et al. Localized cerebral blood flow reductions in patients with heart failure: a study using 99mTc- HMPAO SPECT. J Neuroimaging. 2005 Apr;15(2):150–6.
37. Zuccala G, Onder G, Pedone C, et al; GIFA-ONLUS Study Group [Grupo Italiano di Farmacoepidemiologia nell'Anzanio]. Hypotension and cognitive impairment: selective association in patients with heart failure. Neurology. 2001 Dec 11;57(11):1986–92.
38. Jefferson AL, Poppas A, Paul RH, Cohen RA. Systemic hypoperfusion is associated with executive dysfunction in geriatric cardiac patients. Neurobiol Aging. 2007 Mar;28(3):477–83. Epub 2006 Feb 15.
39. Zuccala G, Cattel C, Manes-Gravina E,et al. Left ventricular dysfunction: a clue to ognitive impairment in older patients with heart failure. Journal of Neurology Neurosurgery and Psychiatry. 1997;63(4):509–12.
40. Jefferson AL, Himali JJ, Beiser AS, et al. Cardiac index is associated with brain aging: the Framingham heart study. Circulation. 2010 Aug 17;122(7):690–7. doi: 10.1161/CIRCULATIONHA.109.905091. Epub 2010 Aug 2..
41. Putzke JD, Williams MA, Rayburn BK, et al. The relationship between cardiac function and neuropsychological status among heart transplant candidates. J Card Fail. 1998 Dec;4(4):295–303.
42. Agha SA, Kalogeropoulos AP, Shih J, et al. Echocardiography and risk prediction in advanced heart failure: incremental value over clinical markers. J Card Fail. 2009 Sep;15(7):586–92. doi: 10.1016/j.cardfail. 2009.03.002. Epub 2009 Apr 28.
43. Qiu C, Winblad B, Marengoni A, et al. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med. 2006 May 8;166(9):1003–8.
44. Georgiadis D, Sievert M, Cencetti S, et al. Cerebrovascular reactivity is impaired in patients with cardiac failure. Eur Heart J. 2000 Mar;21(5):407–13.
45. Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in eart failure. Physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009 Nov 3;54(19):1747–62. doi: 10.1016/j.jacc.2009.05.015.
46. Shibata M, Ohtani R, Ihara M, Tomimoto H. White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke. 2004 Nov;35(11):2598–603. Epub 2004 Oct 7.
47. Marstrand JR, Garde E, Rostrup E, et al. Cerebral perfusion and cerebrovascular eactivity re reduced in white matter hyperintensities. Stroke. 2002 Apr;33(4):972–6.
48. Hatazawa J, Shimosegawa E, Satoh T, et al. Subcortical hypoperfusion associated with asymptomatic white matter lesions on magnetic resonance imaging. Stroke. 1997 Oct;28(10):1944–7.
49. Mujib M, Giamouzis G, Agha SA, et al. Epidemiology of stroke in chronic heart failure patients with normal sinus rhythm: findings from the DIG stroke sub-study. Int J Cardiol. 2010 Oct 29;144(3):389–93. doi: 10.1016/j. ijcard.2009.04.035. Epub 2009 May 12.
50. Woo MA, Macey PM, Fonarow GC, et al. Regional brain gray matter loss in heart failure. J Appl Physiol (1985). 2003 Aug;95(2):677–84. Epub 2003 Apr 25.
51. Sila CA. Cognitive impairment in chronic heart failure. Cleve Clin J Med. 2007 Feb;74 Suppl 1:S132–7.
52. Festa JR, Jia X, Cheung K, et al. Association of low ejection fraction with impaired verbal memory in older patients with heart failure. Arch Neurol. 2011 Aug;68(8):1021–6. doi: 10.1001/archneurol.2011.163.
53. Ekman I, Fagerberg B, Skoog I. The clinical implications of cognitive impairment in lderly patients with chronic heart failure. J Cardiovasc Nurs. 2001 Oct;16(1):47–55.
54. Debette S, Bauters C, Leys D, et al. Prevalence and determinants of cognitive impairment in chronic heart failure patients. Congest Heart Fail. 2007 Jul-Aug;13(4):205–8.
55. Калинин АП, Котов СВ. Неврологические расстройства при эндокринных заболеваниях. Москва: Медицина; 2001. 272 с. [Kalinin AP, Kotov SV. Nevrologicheskie rasstroistva pri endokrinnykh zabolevaniyakh [Neurological disorders in endocrine diseases]. Moscow: Meditsina; 2001. 272 p.]
56. Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev. 2008 Jun;29(4):494–511. doi: 10.1210/er.2007-0034. Epub 2008 Apr 24.
57. Gonder-Frederick LA, Zrebiec JF, Bauchowitz AU, et al. Cognitive function isdisrupted by both hypo- and hyperglycemia in schoolaged children with type 1 diabetes: a field study. Diabetes Care. 2009 Jun;32(6):1001–6. doi: 10.2337/dc08-1722. Epub 2009 Mar 26.
58. Cai XJ, Xu HQ, Lu Y. C-peptide and Diabetic Encephalopathy. Chin Med Sci J. 2011 Jun;26(2):119–25.
59. Чуйко МР, Бодыхов МК, Скворцова ВИ. Характеристика и особенности течения энцефалопатии при инсулинзависимом сахарном диабете. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;(5):4–8. [Chuiko MR, Bodykhov MK, Skvortsova VI. Characteristics and features of encephalopathy with insulin-dependent diabetes mellitus. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;(5):4–8. (In Russ.)].
60. Patino-Fernandez AM, Delamater AM, Applegate EB, et al. Neurocognitive functioning in preschool-age children with type 1 diabetes mellitus. Pediatr Diabetes. 2010 Sep;11(6):424–30. doi: 10.1111/j.1399-5448.2009.00618.x. Epub 2010 Apr 23.
61. Biessels GJ, Luchsinger JA. Pathobiology of diabetic encephalopathy in animal models. Diabetes and the brain contemporary diabetes. N.Y.: Springer; 2010. P. 409–31.
62. Brands AM, Biessels GJ, De Haan EH, et al. The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care. 2005 Mar;28(3):726–35.
63. Perantie DC, Koller JM, Weaver PM, et al. Prospectively determined impact of type 1 diabetes on brain volume during development. Diabetes. 2011 Nov;60(11):3006–14. doi: 10.2337/db11-0589. Epub 2011 Sep 27.
64. Brands AM, Biessels GJ, Kappelle LJ, et al; Utrecht Diabetic Encephalopathy Study Group. Cognitive functioning and brain MRI in patients with type 1 and type 2 diabetes mellitus: a comparative study. Dement Geriatr Cogn Disord. 2007;23(5):343–50. Epub 2007 Mar 20.
65. Ho MS, Weller NJ, Ives FJ, et al. Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus. J Pediatr. 2008 Sep;153(3):385–90. doi: 10.1016/j.jpeds.2008.03.005. Epub 2008 Apr 28.
66. Strachan MW, Reynolds RM, Frier BM, et al. The relationship between type 2 diabetes and dementia. Br Med Bull. 2008;88(1):131–46. doi: 10.1093/bmb/ldn042. Epub 2008 Nov 23.
67. Fontbonne A, Berr С, Ducimetiere P, Alperovitch A. Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care. 2001 Feb;24(2):366–70.
68. Messier C. Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging. Neurobiol Aging. 2005 Dec;26 Suppl 1:26–30. Epub 2005 Oct 19.
69. Mijnhout GS, Scheltens P, Diamant M, et al Diabetic encephalopathy: A concept in need of a definition. Diabetologia. 2006 Jun;49(6):1447–8. Epub 2006 Apr 6.
70. Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006 Jan;5(1):64–74.
71. Ott A, Stolk RP, Hofman A, et al. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia. 1996 Nov;39(11):1392–7.
72. Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology. 1995 Jun;45(6):1161–8.
73. Строков ИА, Моргоева ФЭ, Строков КИ и др. Терапевтическая коррекция диабетической полиневропатии и энцефалопатии Актовегином. Русский медицинский журнал. 2006;(9):698–703. [Strokov IA, Morgoeva FE, Strokov KI, et al. Therapeutic correction of diabetic polyneuropathy and encephalopathy with Actovegin. Russkii meditsinskii zhurnal. 2006;(9):698–703. (In Russ.)] .
74. Чугунов ПА, Семенова ИВ. Сахарный диабет и когнитивные нарушения. Сахарный диабет. 2008;38(1):61–8. [Chugunov PA, Semenova IV. Diabetes and cognitive impairment. Sakharnyi diabet. 2008;38(1):61–8. (In Russ.)].
75. Reaven G, Thompson L, Nahum D, Haskins E. Relationship between hyperglycemia and cognitive function in older NIDDM patients. Diabetes Care. 1990 Jan;13(1):16–21.
76. Nielson KA, Nolan JH, Berchtold NC, et al. Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer’s disease? J Am Geriatr Soc. 1996 Aug;44(8):897–904.
77. Sima AA, Kamiya H, Li ZG. Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes. Eur J Pharmacol. 2004 Apr 19;490(1–3):187–97.
78. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002 May 15;287(19):2570–81.
79. Ефимов АС. Диабетические ангиопатии. Москва: Медицина; 1989. 288 с. [Efimov AS. iabeticheskie angiopatii [Diabetic angiopathies]. Moscow: Meditsina; 1989. 288 p.]
80. Wredling R, Levander S, Adamson U, Lins PE. Permanent neuropsychological impairment after recurrent episodes of severe hypoglicaemia in men. Diabetologia. 1990 Mar;33(3):152–7.
81. Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Effect of angiotensin converting enzyme inhibition. Hypertension. 1991 Aug;18(2):132–41.
82. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease pulations: an occult burden. Adv Chronic Kidney Dis. 2008 Apr;15(2):123–32. doi: 10.1053/j.ackd.2008.01.010.
83. Fazekas G, Fazekas F, Schmidt R, et al. Brain MRI findings and cognitive impairment in patients undergoing chronic hemodialysis treatment. J Neurol Sci. 1995 Dec;134(1–2):83–8.
84. Kurella M, Chertow GM, Fried LF, et al. Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol. 2005 Jul;16(7):2127–33. Epub 2005 May 11.
85. Seliger SL, Siscovick DS, Stehman-Breen CO, et al. Moderate renal impairment and risk f dementia among older adults: The Cardiovascular Health Cognition study. J Am Soc Nephrol. 2004 Jul;15(7):1904–11.
86. Slinin Y, Paudel ML, Ishani A, et al.; Osteoporotic Fractures in Men Study Group. Kidney function and cognitive performance and decline in older men. J Am Geriatr Soc. 2008 Nov;56(11):2082–8. doi: 10.1111/j.1532-5415.2008.01936.x. Epub 2008 Sep 15.
87. Khatri M, Nickolas T, Moon YP, et al. CKD associates with cognitive decline. J Am Soc Nephrol. 2009 Nov;20(11):2427–32. doi: 10.1681/ASN.2008101090. Epub 2009 Sep 3.
88. Elias MF, Elias PK, Seliger SL, et al. Chronic kidney disease, creatinine and cognitive functioning. Nephrol Dial Transplant. 2009 Aug;24(8):2446–52. doi: 10.1093/ndt/gfp107. Epub 2009 Mar 18.
89. Garcia A, Zanibbi K. Homocysteine and cognitive function in elderly people. CMAJ. 2004 Oct 12;171(8):897–904.
90. Дамулин ИВ. Патогенетические, диагностические и терапевтические аспекты сосудистых когнитивных нарушений. Consilium Medicum. 2006;(8):80–5. [Damulin IV. Pathogenetic, diagnostic and therapeutic aspects of vascular cognitive impairment. Consilium Medicum. 2006;(8):80–5. (In Russ.)].
91. Stein G, Mü ller A, Busch M, et al. Homocysteine, its metabolites, and B-group vitamins in renal transplant patients. Kidney Int Suppl. 2001 Feb;78:S262–5.
92. Prins ND, Den Heijer T, Hofman A, et al.; Rotterdam Scan Study. Homocysteine and ognitive function in the elderly: the Rotterdam Scan Study. Neurology. 2002 Nov 12;59(9):1375–80.
93. Sachdev P. Homocysteine, cerebrovascular disease and brain atrophy. J Neurol Sci. 2004 Nov 15;226(1–2):25–9.
94. Рогова ИВ, Фомин ВВ, Дамулин ИВ и др. Сосудистые когнитивные нарушения при хронической болезни почек. Неврология, нейропсихиатрия, психосоматика. 2015;7(1):11–8. [Rogova IV, Fomin VV, Damulin IV, et al. Vascular cognitive impairments in chronic kidney disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2015;7(1):11–8. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2015-1-11-18
95. Гусев ЕИ, Скворцова ВИ. Ишемия головного мозга. Москва: Медицина; 2001. 328 с. [Gusev EI, Skvortsova VI. Ishemiya golovnogo mozga [Brain ischemia]. Moscow: Meditsina; 2001. 328 p.]
96. Захаров ВВ, Дамулин ИВ, Яхно НН. Медикаментозная терапия деменций. Клиническая фармакология и терапия. 1994;3(4):69–75. [Zakharov VV, Damulin IV, Yakhno NN. Drug therapy of dementia. Clinical pharmacology and therapy. 1994;3(4):69–75. (In Russ.)].
97. Беленичев ИФ, Сидорова ИВ. Тиоцетам – новый церебропротективный и ноотропный препарат. Здоровье Украины. 2004;(13–16):41. [Belenichev IF, Sidorova IV. Tiocetam – new cerebroprotective and nootropic drug. Zdorov'e Ukrainy. 2004;(13–16):41. (In Russ.)].
98. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005 Summer;11(2):169–82.
99. Беленичев ИФ, Мазур ИА, Сидорова ИВ. Исследование ноотропной и стресспротективной активности препарата «Тиоцетам» в условиях моделирования экстремальных состояний. Экспериментальная и клиническая физиология и биохимия. 2005;(3):7–15. [Belenichev IF, Mazur IA, Sidorova IV. The study of nootropic and stressreduction activity of the drug «Tiocetam» in the modelling of extreme states. Eksperimental'naya i klinicheskaya fiziologiya i biokhimiya. 2005;(3):7–15. (In Russ.)].
100. Боброва ВИ, Колесник ЮМ, Беленичев ИФ, Демченко АВ. Тиоцетам в комплексной терапии хронической ишемии головного мозга. Запорожский медицинский журнал. 2010;12(5):130–5. [Bobrova VI, Kolesnik YuM, Belenichev IF, Demchenko AV. Tiocetam in the treatment of chronic cerebral ischemia. Zaporozhskii meditsinskii zhurnal. 2010;12(5):130–5. (In Russ.)].
101. Дзяк ЛА, Зорин НА, Анин ЕА и др. Результаты клинического применения антиоксиданта тиотриазолина в комплексном лечении больных с тяжелой черепно-мозговой травмой. Актуальнi питання фармацевтичної та медичної науки i практики. Запорiжжя: ЗДМУ. 2002;(8):146–51. [Dzyak LA, Zorin NA, Anin EA i dr. The results of the clinical use of antioxidant thiotriazoline in complex treatment of patients with severe traumatic brain injury. Aktual'ni pitannya farmatsevtichnoї ta medichnoї nauki i praktiki. Zaporizhzhya: ZDMU. 2002;(8):146–51. (In Russ.)].
102. Ковальчук ВВ. Использование нейроцитопротекторов для повышения эффективности реабилитации пациентов после инсульта. Неврология, нейропсихиатрия, психосоматика. 2014;6(1):30–4. [Koval'chuk VV. The use of neurocytoprotectors to improve rehabilitation of patients after cerebrovascular accident. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(1):30–4. (In Russ.)].DOI: http://dx.doi.org/10.14412/2074-2711- 014-1-30-34
103. Кравчун НА, Казаков АВ, Чернявская ИВ. Использование Тиоцетама у больных с сочетанной эндокринной патологией. Здоровье Украины. 2006;(17):2–3. [Kravchun NA, Kazakov AV, Chernyavskaya IV. The use of Thiocetam in patients with associated endocrine disorders. Zdorov'e Ukrainy. 2006;(17):2–3. (In Russ.)].
104. Мищенко ТС, Мищенко ВН, Здесенко ИВ. Новые возможности в терапии больных с мозговым инсультом. Международный неврологический журнал. 2013;(2):6–13. [Mishchenko TS, Mishchenko VN, Zdesenko IV. New possibilities in the treatment of patients with cerebral stroke. Mezhdunarodnyi nevrologicheskii zhurnal. 2013;(2):6–13. (In Russ.)].
105. Волошин НА, Визир ВА, Волошина ИН. Тиотриазолин, тиоцетам, тиодарон в практике врача. Запорожье: ЗГМУ; 2008. 220 с. [Voloshin NA, Vizir VA, Voloshina IN. Tiotriazolin, tiotsetam, tiodaron v praktike vracha [Thiotriazolin, tiocetam, tiodaron in doctor's practice]. Zaporozh'e: ZGMU; 2008. 220 p.]
106. Бойко А, Лебедева А, Щукин И и др.Новые подходы к ведению пациентов с умеренными когнитивными расстройствами при хронической ишемии головного мозга. Врач. 2014;(12):54–9. [Boiko A, Lebedeva A, Shchukin I, et al. New approaches to the treatment of patients with mild cognitive disorders in chronic cerebral ischemia. Vrach. 2014;(12):54–9. (In Russ.)].
107. Антонова НА, Чижова КЕ,Шоломов ИИ. Применение препарата Тиоцетам у пациентов, пренесших инфаркт головного мозга в бассейне левой средней мозговой артерии. Неврологический вестник. 2014;46(1):86–8. [Antonova NA, Chizhova KE, Sholomov II. The use of Tiocetam in patients with a stroke in the basin of the left middle cerebral artery. Nevrologicheskii vestnik. 2014;46(1):86–8. (In Russ.)].
Review
For citations:
Pizova N.V. Cognitive impairments in some cardiovascular and somatic diseases. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(2):93-100. (In Russ.) https://doi.org/10.14412/2074-2711-2015-2-93-100
Views: 1188
Email this article 